The Daily Byte
Breaking
Welcome to The Daily Byte — real stories from across Pakistan.
Saturday, 21 November 2026 · Pakistan

The Daily Byte

Stories from Pakistan that deserve to be heard
Minor Markets

Capricor Shares Plunge After FDA Rejects Drug

By The Daily Byte ·21 Nov 2026 ·3 min read
Capricor Therapeutics laboratory with company logo and scientists at work

Shares in Capricor Therapeutics plunged in extended trading on Friday after the US Food and Drug Administration declined to approve the company's experimental cell therapy for Duchenne muscular dystrophy, citing serious problems with the integrity of the trial data.

The shares were down 72 per cent in extended trading, according to Reuters, after the regulator said the evidence for the therapy, known as deramiocel, did not meet the standard for approval. Capricor had been seeking approval for the treatment to preserve upper-limb function in patients with the fatal inherited disease.

Duchenne muscular dystrophy primarily affects boys and causes progressive muscle weakness, loss of mobility, heart complications and premature death. The condition affects roughly 15,000 Americans, mostly boys, and there is no cure.

Why the FDA said no

The agency said serious data integrity problems in a key clinical trial meant the evidence could not be relied upon. The problems included unauthorised changes to the statistical analysis plan after the trial had begun, violations of the rules designed to keep patients and researchers from knowing who received the treatment, and other protocol breaches.

The FDA said the violations "compromise the reliability of the study data" and that the data was "not considered reliable or interpretable" as proof that the treatment works. Capricor criticised the decision, with chief executive Linda Marban saying: "The FDA has failed the Duchenne community" and calling the rejection "indefensible".

A second setback

The decision is the second rejection for deramiocel and adds to a string of regulatory setbacks for the Beverly Hills-based biotech. In July, the FDA's advisers voted nine to three that the evidence presented at the time did not establish the therapy's effectiveness in Duchenne-related heart disease.

Capricor subsequently amended its application with new data and narrowed its proposed use to preserving arm and hand movement, in an effort to salvage the application. The regulator was not persuaded, and the decision had been expected by Sunday 22 November, the FDA's action date for the application.

The setback deepens a brutal year for the company, whose shares had already fallen by more than 73 per cent in 2026 before Friday's session. Analysts at Oppenheimer had expected approval around the action date and maintained a 54-dollar price target on the stock, arguing it could reach 50 dollars a share on a green light.

What happens next

Capricor said it is weighing its next steps, including further job cuts on top of a reduction of roughly 10 per cent of its headcount carried out earlier this month. The rejection threatens the company's lead experimental asset and clouds its commercial prospects, since deramiocel is the treatment around which its near-term plans were built.

For families living with Duchenne, the decision closes off a treatment they had hoped would slow the loss of muscle function. Whether Capricor can repair the trial data, run a new study, or find another route to approval will decide whether deramiocel has any future at all.